Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Trial Results: Apollomics Inc. announced that its Phase 3 trial of uproleselan for relapsed or refractory acute myeloid leukemia did not show a favorable benefit compared to chemotherapy alone, with median overall survival being lower in the uproleselan group (9.3 months) than in the control group (14.3 months).
Future Plans: The company plans to conclude the uproleselan program and submit full trial results for presentation at a future medical conference, while also focusing on its lead oncology program, vebreltinib, which is currently in clinical trials.
Trade with 70% Backtested Accuracy
Analyst Views on APLM
About APLM
About the author
Apollomics Narrows H1 Loss to $12.56M Amid Revenue Growth
- Loss Narrowing: Apollomics reported a narrowed loss of $12.56 million for the first half, down from $35.21 million year-over-year, indicating improved financial management and boosting investor confidence.
- R&D Expense Reduction: Research and development expenses decreased significantly from $16.93 million to $4.62 million, reflecting effective cost control measures that could enhance future profitability.
- Revenue Growth: The company generated $8.5 million in revenue for the first half, compared to no revenue in the same period last year, demonstrating positive progress in market outreach and product development, potentially laying the groundwork for sustained growth.
- Strong Cash Position: Apollomics holds $2.1 million in cash and equivalents, which is expected to fund operations into Q3 2026, thereby strengthening its capacity for ongoing clinical trials and research investments.
Apollomics Reports 64% Reduction in Net Loss to $12.5 Million for H1 2025
- Financial Position Improvement: As of June 30, 2025, Apollomics reported cash and cash equivalents of $2.1 million, a significant decrease from $9.8 million as of December 31, 2024, indicating pressure on the company's liquidity management.
- Significant Reduction in R&D Expenses: R&D expenses for the first half of 2025 were $4.6 million, a 73% decrease from $16.9 million in the same period of 2024, reflecting a more cautious approach to research investments by the company.
- Increase in Administrative Expenses: General and administrative expenses rose to $14.5 million in the first half of 2025, up 42% from $10.2 million in the first half of 2024, highlighting cost pressures in operational management.
- Substantial Decrease in Loss Per Share: The net loss per share for the first half of 2025 was $11.37, down 70% from $37.53 in the same period of 2024, demonstrating significant progress in the company's efforts to control losses.
Apollomics Reveals Updates to Board of Directors and Committee Structure
Board Changes: Apollomics Inc. announced the resignation of Mr. Po-Jen Hsueh from its board, with Dr. Ya-Chi (Claudia) Huang appointed to fill the vacancy and join the Audit and Nominating Committees.
New Director's Background: Dr. Huang has extensive experience in biotechnology investment and corporate governance, currently serving as Assistant Vice President at Maxpro Ventures and previously as Investment Manager at Diamond Biofund.
Company Focus: Apollomics is a clinical-stage biopharmaceutical company specializing in oncology therapies, with its lead program, vebreltinib, currently in a Phase 2 clinical trial for non-small cell lung cancer.
Forward-Looking Statements: The press release includes forward-looking statements regarding Apollomics' strategies and anticipated outcomes, cautioning that these are subject to risks and uncertainties.
Lucas GC Shares Surge Over 36%; Check Out 20 Stocks Making Moves in Premarket Trading
Lucas GC Limited Financial Results: Lucas GC Limited's shares surged 36.2% to $3.73 in pre-market trading after reporting H1 2025 earnings per share (EPS) of $1.47 on sales of $54.008 million.
Other Notable Gainers: MSP Recovery, Inc. saw a dramatic 262% increase to $0.7706, while SMX (Security Matters) Public Limited Company rose 72% to $3.47, among other significant pre-market gains.
Stocks Experiencing Losses: ZOOZ Strategy Ltd. dropped 28.3% to $1.01, and Alvotech fell 21.6% to $6.00, reflecting a trend of declines in several stocks after previous gains.
Market Overview: The pre-market trading session showed a mix of significant gains and losses across various stocks, indicating volatility in the market following recent trading activities.
Apollomics Confirms Ongoing Nasdaq Listing After Hearing Cancellation
Nasdaq Compliance: Apollomics Inc. has received confirmation from Nasdaq that it is in compliance with listing requirements, leading to the cancellation of its appeal hearing regarding a previous delisting notification.
Company Overview: Apollomics is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with its lead drug candidate, vebreltinib, currently in Phase 2 trials for treating non-small cell lung cancer and other advanced tumors.
Nasdaq Suspends Trading of Apollomics Inc., Ltd.
Trading Halt Announcement: Nasdaq announced a trading halt for Apollomics Inc., Ltd. on September 17, 2025, at 14:37:17 Eastern Time due to a request for additional information from the company.
Current Share Prices: The last recorded sale price for Apollomics' ordinary shares was $18.4331, while the warrants were priced at $0.0191, with trading remaining halted until the company complies with Nasdaq's information request.
Apollomics Narrows H1 Loss to $12.56M Amid Revenue Growth
- Loss Narrowing: Apollomics reported a narrowed loss of $12.56 million for the first half, down from $35.21 million year-over-year, indicating improved financial management and boosting investor confidence.
- R&D Expense Reduction: Research and development expenses decreased significantly from $16.93 million to $4.62 million, reflecting effective cost control measures that could enhance future profitability.
- Revenue Growth: The company generated $8.5 million in revenue for the first half, compared to no revenue in the same period last year, demonstrating positive progress in market outreach and product development, potentially laying the groundwork for sustained growth.
- Strong Cash Position: Apollomics holds $2.1 million in cash and equivalents, which is expected to fund operations into Q3 2026, thereby strengthening its capacity for ongoing clinical trials and research investments.
Apollomics Reports 64% Reduction in Net Loss to $12.5 Million for H1 2025
- Financial Position Improvement: As of June 30, 2025, Apollomics reported cash and cash equivalents of $2.1 million, a significant decrease from $9.8 million as of December 31, 2024, indicating pressure on the company's liquidity management.
- Significant Reduction in R&D Expenses: R&D expenses for the first half of 2025 were $4.6 million, a 73% decrease from $16.9 million in the same period of 2024, reflecting a more cautious approach to research investments by the company.
- Increase in Administrative Expenses: General and administrative expenses rose to $14.5 million in the first half of 2025, up 42% from $10.2 million in the first half of 2024, highlighting cost pressures in operational management.
- Substantial Decrease in Loss Per Share: The net loss per share for the first half of 2025 was $11.37, down 70% from $37.53 in the same period of 2024, demonstrating significant progress in the company's efforts to control losses.
Apollomics Reveals Updates to Board of Directors and Committee Structure
Board Changes: Apollomics Inc. announced the resignation of Mr. Po-Jen Hsueh from its board, with Dr. Ya-Chi (Claudia) Huang appointed to fill the vacancy and join the Audit and Nominating Committees.
New Director's Background: Dr. Huang has extensive experience in biotechnology investment and corporate governance, currently serving as Assistant Vice President at Maxpro Ventures and previously as Investment Manager at Diamond Biofund.
Company Focus: Apollomics is a clinical-stage biopharmaceutical company specializing in oncology therapies, with its lead program, vebreltinib, currently in a Phase 2 clinical trial for non-small cell lung cancer.
Forward-Looking Statements: The press release includes forward-looking statements regarding Apollomics' strategies and anticipated outcomes, cautioning that these are subject to risks and uncertainties.
Lucas GC Shares Surge Over 36%; Check Out 20 Stocks Making Moves in Premarket Trading
Lucas GC Limited Financial Results: Lucas GC Limited's shares surged 36.2% to $3.73 in pre-market trading after reporting H1 2025 earnings per share (EPS) of $1.47 on sales of $54.008 million.
Other Notable Gainers: MSP Recovery, Inc. saw a dramatic 262% increase to $0.7706, while SMX (Security Matters) Public Limited Company rose 72% to $3.47, among other significant pre-market gains.
Stocks Experiencing Losses: ZOOZ Strategy Ltd. dropped 28.3% to $1.01, and Alvotech fell 21.6% to $6.00, reflecting a trend of declines in several stocks after previous gains.
Market Overview: The pre-market trading session showed a mix of significant gains and losses across various stocks, indicating volatility in the market following recent trading activities.
Apollomics Confirms Ongoing Nasdaq Listing After Hearing Cancellation
Nasdaq Compliance: Apollomics Inc. has received confirmation from Nasdaq that it is in compliance with listing requirements, leading to the cancellation of its appeal hearing regarding a previous delisting notification.
Company Overview: Apollomics is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with its lead drug candidate, vebreltinib, currently in Phase 2 trials for treating non-small cell lung cancer and other advanced tumors.
Nasdaq Suspends Trading of Apollomics Inc., Ltd.
Trading Halt Announcement: Nasdaq announced a trading halt for Apollomics Inc., Ltd. on September 17, 2025, at 14:37:17 Eastern Time due to a request for additional information from the company.
Current Share Prices: The last recorded sale price for Apollomics' ordinary shares was $18.4331, while the warrants were priced at $0.0191, with trading remaining halted until the company complies with Nasdaq's information request.
